Angle PLC Shares Rise on Cancer Patient Blood Sample Analysis
04 Enero 2024 - 3:10AM
Noticias Dow Jones
By Ian Walker
Angle PLC shares rose as much as 41% in early trade after the
company said that DNA molecular analysis from cancer patient blood
samples provides insight into the progression and treatment of
cancers for those patients, and enables it to expand product sales
and pharmaceutical service offerings.
Shares at 0834 GMT were up 4.50 pence, or 34%, at 17.75 pence
having peaked at 18.63 pence earlier in the session. However, they
are down 63% over the past 12 months.
The U.K. liquid-biopsy company said Thursday that the results
come from 47 patient samples in breast, lung, prostate and ovarian
cancers.
"Today's breakthrough is the critical next step post the [Food
and Drug Administration] clearance to show in a sample-to-answer
format the potential clinical value of NGS [next generation
sequencing] molecular analysis on a repeat basis of living cancer
cells harvested from patient blood samples," Chief Executive
Officer Andrew Newland said.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
January 04, 2024 03:55 ET (08:55 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Angle (LSE:AGL)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Angle (LSE:AGL)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024